Literature DB >> 28268256

Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Jonathan L C Lee1, Leandro J Bertoglio2, Francisco S Guimarães3, Carl W Stevenson4.   

Abstract

Learning to associate cues or contexts with potential threats or rewards is adaptive and enhances survival. Both aversive and appetitive memories are therefore powerful drivers of behaviour, but the inappropriate expression of conditioned responding to fear- and drug-related stimuli can develop into anxiety-related and substance abuse disorders respectively. These disorders are associated with abnormally persistent emotional memories and inadequate treatment, often leading to symptom relapse. Studies show that cannabidiol, the main non-psychotomimetic phytocannabinoid found in Cannabis sativa, reduces anxiety via 5-HT1A and (indirect) cannabinoid receptor activation in paradigms assessing innate responses to threat. There is also accumulating evidence from animal studies investigating the effects of cannabidiol on fear memory processing indicating that it reduces learned fear in paradigms that are translationally relevant to phobias and post-traumatic stress disorder. Cannabidiol does so by reducing fear expression acutely and by disrupting fear memory reconsolidation and enhancing fear extinction, both of which can result in a lasting reduction of learned fear. Recent studies have also begun to elucidate the effects of cannabidiol on drug memory expression using paradigms with translational relevance to addiction. The findings suggest that cannabidiol reduces the expression of drug memories acutely and by disrupting their reconsolidation. Here, we review the literature demonstrating the anxiolytic effects of cannabidiol before focusing on studies investigating its effects on various fear and drug memory processes. Understanding how cannabidiol regulates emotion and emotional memory processing may eventually lead to its use as a treatment for anxiety-related and substance abuse disorders. Linked Articles This article is part of a themed section on Pharmacology of Cognition: a Panacea for Neuropsychiatric Disease? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.19/issuetoc.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28268256      PMCID: PMC5595771          DOI: 10.1111/bph.13724

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  115 in total

Review 1.  Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on.

Authors:  A P Carobrez; L J Bertoglio
Journal:  Neurosci Biobehav Rev       Date:  2005-08-09       Impact factor: 8.989

Review 2.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

3.  Roles of hippocampal N-methyl-D-aspartate receptors and calcium/calmodulin-dependent protein kinase II in amphetamine-produced conditioned place preference in rats.

Authors:  Shojiro Sakurai; Lifa Yu; Soon-Eng Tan
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

Review 4.  Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.

Authors:  Angelo A Izzo; Francesca Borrelli; Raffaele Capasso; Vincenzo Di Marzo; Raphael Mechoulam
Journal:  Trends Pharmacol Sci       Date:  2009-09-02       Impact factor: 14.819

5.  Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats.

Authors:  Leonardo B M Resstel; Sâmia R L Joca; Fabrício A Moreira; Fernando M A Corrêa; Francisco S Guimarães
Journal:  Behav Brain Res       Date:  2006-06-15       Impact factor: 3.332

6.  Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors.

Authors:  Alline Cristina Campos; Frederico Rogério Ferreira; Francisco Silveira Guimarães
Journal:  J Psychiatr Res       Date:  2012-09-11       Impact factor: 4.791

Review 7.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

8.  Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

Authors:  Mateus M Bergamaschi; Regina Helena Costa Queiroz; Marcos Hortes Nisihara Chagas; Danielle Chaves Gomes de Oliveira; Bruno Spinosa De Martinis; Flávio Kapczinski; João Quevedo; Rafael Roesler; Nadja Schröder; Antonio E Nardi; Rocio Martín-Santos; Jaime Eduardo Cecílio Hallak; Antonio Waldo Zuardi; José Alexandre S Crippa
Journal:  Neuropsychopharmacology       Date:  2011-02-09       Impact factor: 7.853

9.  Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze.

Authors:  F S Guimarães; J C de Aguiar; R Mechoulam; A Breuer
Journal:  Gen Pharmacol       Date:  1994-01

Review 10.  Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.

Authors:  Yasmin L Hurd; Michelle Yoon; Alex F Manini; Stephanie Hernandez; Ruben Olmedo; Maria Ostman; Didier Jutras-Aswad
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more
  41 in total

Review 1.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  A time-dependent contribution of hippocampal CB1 , CB2 and PPARγ receptors to cannabidiol-induced disruption of fear memory consolidation.

Authors:  Ana Maria Raymundi; Thiago R da Silva; Aleksander R Zampronio; Francisco S Guimarães; Leandro J Bertoglio; Cristina A J Stern
Journal:  Br J Pharmacol       Date:  2020-01-21       Impact factor: 8.739

3.  Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.

Authors:  Roger Hudson; Justine Renard; Christopher Norris; Walter J Rushlow; Steven R Laviolette
Journal:  J Neurosci       Date:  2019-09-30       Impact factor: 6.167

Review 4.  Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals.

Authors:  Elizabeth M Williamson; Xinmin Liu; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2020-02-06       Impact factor: 8.739

5.  Systemic Injections of Cannabidiol Enhance Acetylcholine Levels from Basal Forebrain in Rats.

Authors:  Eric Murillo-Rodríguez; Gloria Arankowsky-Sandoval; Nuno Barbosa Rocha; Rodrigo Peniche-Amante; André Barciela Veras; Sérgio Machado; Henning Budde
Journal:  Neurochem Res       Date:  2018-06-06       Impact factor: 3.996

Review 6.  Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.

Authors:  G M Mandolini; M Lazzaretti; A Pigoni; L Oldani; G Delvecchio; P Brambilla
Journal:  Epidemiol Psychiatr Sci       Date:  2018-05-23       Impact factor: 6.892

7.  Natural Cannabinoids as Templates for Sleep Disturbances Treatments.

Authors:  Eric Murillo-Rodríguez; Sérgio Machado; Claudio Imperatori; Tetsuya Yamamoto; Henning Budde
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence.

Authors:  Madison Wright; Patricia Di Ciano; Bruna Brands
Journal:  Cannabis Cannabinoid Res       Date:  2020-09-02

Review 9.  Cannabidiol: pharmacology and therapeutic targets.

Authors:  Stevie C Britch; Shanna Babalonis; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2020-11-21       Impact factor: 4.530

10.  Pharmacology of cognition: a panacea for neuropsychiatric disease?

Authors:  Sarah J Bailey; Joanna C Neill; Paula M Moran
Journal:  Br J Pharmacol       Date:  2017-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.